Recursion Prices $200 Million Stock Sale At $3.25 A Share, Says Cash Now Lasts Into 2029
The offering of 61,540,000 shares came with a $561 million preliminary cash estimate and a Sanofi milestone worth $10 million.
Recursion Pharmaceuticals priced an underwritten offering of 61,540,000 Class A shares at $3.25 each, for expected gross proceeds of about $200 million, according to an 8-K filed Thursday. The company paired the sale with a cash update, trial data and word that Sanofi has optioned a drug candidate from their collaboration.
The offering and the cash
All the shares are being sold by the company. Closing is expected on or about October 16, before underwriting discounts and offering expenses are deducted.
The 8-K estimates cash, cash equivalents and restricted cash of about $561 million at September 30. That figure is preliminary and unaudited, and the filing says the auditor has done no work on it. Recursion expects that cash, together with the offering, to fund operations into 2029.
The estimate includes about $86 million in net proceeds from selling 23,696,330 shares through its at-the-market program during the quarter ended September 30. Executive officers and directors agreed to a 45-day lock-up on selling their own shares.
A company press release said investors in the sale included Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest and Driehaus Capital Management.
The Sanofi option
Sanofi optioned the first development candidate from the two companies' research collaboration, a potential first-in-class oral small molecule aimed at a dual target in inflammatory disease. The option triggered a $10 million milestone payment, bringing upfront and milestone payments under the collaboration to $144 million.
Recursion remains eligible for more than $300 million in further milestones on this program, plus royalties averaging in the low double digits if the drug is commercialized. It is the sixth progress-based milestone across five programs.
The company said the payment ends its operational requirements on this candidate, so future payments are profit. Sanofi will fund and lead development, with phase 1 trials expected in 2027.
"The most important test of any technology platform in drug discovery is whether it can translate into differentiated medicines," said Najat Khan, Recursion's President and Chief Executive Officer.
Trial updates and what comes next
In the TUPELO study of REC-4881 for familial adenomatous polyposis, 87% of 16 efficacy-evaluable patients had lower total polyp burden, with a 47% median reduction at week 13. The company anticipates starting a registrational trial in 2027, pending FDA talks.
For REC-1245, 11 of 12 patients dosed at 45 mg or 65 mg (91.7%) achieved disease control at eight weeks. Three had partial responses, two of them confirmed. At 65 mg, three of four evaluable patients had dose-limiting toxicities, so 45 mg was chosen for expansion cohorts.
Fuller REC-4881 data go to a gastrointestinal cancer meeting on Monday, November 2. More REC-1245 data are expected in the second half of 2026.
The $3.25 price compares with a $3.74 close on Wednesday, the session before the announcement.
Sources
- 8-K Filing — RECURSION PHARMACEUTICALS, INC. (RXRX) — SEC EDGAR
- Exhibit exhibit991-sanofipr.htm — RECURSION PHARMACEUTICALS, INC. 8-K exhibit — SEC EDGAR
- Exhibit exhibit992-businessupdate.htm — RECURSION PHARMACEUTICALS, INC. 8-K exhibit — SEC EDGAR
- Exhibit rxrx_octoberx2026xfinal.htm — RECURSION PHARMACEUTICALS, INC. 8-K exhibit — SEC EDGAR
- Exhibit exhibit994-pricingpr.htm — RECURSION PHARMACEUTICALS, INC. 8-K exhibit — SEC EDGAR